Thyroid nodules are quite common, and the determination of a nodule of concern is
complex, involving serum testing, radiology and, in some cases, pathological evaluation. For …

Dear Editor, RAS mutations are present in one third of follicular-cell derived thyroid cancer
(TC)(1). They are more frequent in follicular TC and in follicular subtype of papillary TC …

Background: The dabrafenib plus trametinib combination (DT) has revolutionized the
treatment of BRAFV600E-mutated anaplastic thyroid carcinoma (BRAFm-ATC). However …

Simple Summary Medullary thyroid carcinoma (MTC) is driven by a small number of
pathogenic genetic variants and tumours usually exhibit a correspondingly low tumour …

Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment
of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p …

Selpercatinib, a selective RET kinase inhibitor, has demonstrated remarkable efficacy in
treating patients with advanced medullary (MTC) and differentiated thyroid cancer with RET …

The 6-fold increase in the incidence of differentiated thyroid cancer over the past 30 years in
industrialized countries can be mainly attributed to improved detection. At the same time, in …

Cancer of the thyroid gland may be a less common condition than carcinoma of the breast,
lung, or colon, but it occurs with suf? cient frequency to constitute a major problem that is of …

After decades of increase due to overdiagnosis of low-risk Differentiated Thyroid Cancer
(LRDTC), incidence rates have declined since 2014 and now stabilised. However, there …

Background RAS mutations are present in one third of follicular-cell–derived thyroid cancers
(TCs) and are more frequent in follicular TCs and follicular variant of papillary TCs, with …